Long-term study show the nine-valent HPV vaccine greatly reduces the risk of HPV infection and HPV-associated diseases
Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer. And thanks to an international effort to improve the vaccine, the medical community is one step closer to preventing more HPV-associated diseases. The researchers, including those from Moffitt Cancer Center, published the final results of a study showing the newest vaccine is highly effective at preventing HPV infection and disease. The study was published this week in The Lancet.
HPV is an extremely common virus. It is estimated that by age 50, four out of five women have been infected with the virus at one point throughout their lifetimes. HPV causes ailments such as genital and anal warts and, in some instances, continued infection can lead to the development of benign or cancerous growths of the cervix, vulva, vagina, anus, penis, tonsils, and base of the tongue. There are more than 100 types of HPV, but only approximately 13 types are associated with cancer development. HPV 16 and 18 alone are estimated to cause 70 percent of all cervical cancers.
Two existing HPV vaccines, Cervarix® and Gardasil®, are effective at preventing disease caused by HPV types 16 and 18, while Gardasil also protects against genital warts caused by HPV 6 and 11. However, these vaccines do not protect against all HPV types that are associated with cancer. Scientists developed an improved vaccine called 9vHPV that targets HPV 16, 18, 6, and 11, and an additional 5 HPV types that are the next most commonly associated with cervical cancer (HPV 31, 33, 45, 52 and 58).
“Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV-related vulvar and vaginal cancer, 70 to 85 percent of high-grade cervical disease in females, and approximately 90 percent of HPV-related anal cancer and genital warts in males and females worldwide,” explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.
Researchers from 18 countries and 105 study sites conducted a phase 3 study to compare the activity of the new 9vHPV vaccine against the older vaccine that protected against four HPV types (Gardasil). The study randomized 14,215 women 16 to 26 years of age to either 9vHPV or Gardasil, and the study participants were medically followed for 6 years after vaccination.
The study found that the 9vHPV vaccine has long-term activity against HPV infection and disease. The 9vHPV vaccine reduced the risk of developing HPV 31/33/45/52/58-related cervical, vulvar, and vaginal disease by 97.7 percent when compared to Gardasil®, and the two vaccines had similar activity at preventing HPV 6/11/16/18-associated disease. The 9vHPV vaccine was also highly effective at reducing the risk of having HPV 31/33/45/52/58-associated cervical cell abnormalities, biopsies, and definitive therapies.
9vHPV, known as Gardasil 9, became available in 2015 to protect females and males ages 9 through 26 years against HPV-associated cancers and genital warts. Scientists hope its continued use will greatly reduce the incidence and mortality of HPV-associated diseases.
“The 9vHPV vaccine is licensed in over 40 countries for the prevention of HPV-related anogenital cancers and pre-cancer, and genital warts. The results of this study support comprehensive vaccination programs and inform public health decision related to implementation,” said Giuliano.
Learn more: New Study Finds Improved Vaccine That Protects against Nine Types of HPV is Highly Effective
The Latest on: HPV vaccine
[google_news title=”” keyword=”HPV vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equityon May 8, 2024 at 3:59 pm
Although several countries have adopted a single-dose human papillomavirus (HPV) vaccination strategy, many other countries continue to include multiple doses in their vaccination programmes. There ...
- 5 Reasons To Get The HPV Vaccine For You & Your Daughters Now!on May 8, 2024 at 3:28 am
There’s been a lot of talk on cervical cancer recently, and a lot of awareness is being created around it. For those who don’t already know, cervical cancer ...
- Why adults are advised to consider HPV vaccinationon May 7, 2024 at 5:00 pm
Dr. Christine Palmay says that when she talks to her patients about the HPV vaccines, she tells them it’s a vaccine against certain HPV-related cancers. HPV, or the human papillomavirus, is the most ...
- HPV-related cancer vaccine now available at HSAon May 7, 2024 at 12:31 pm
The Gardasil 9 vaccine, which has been approved for the prevention of certain cancers and diseases caused by the human papillomavirus is now available at the HSA.
- Taipei expanding free HPV vaccine to boyson May 7, 2024 at 9:00 am
From Sept. 1, eighth-grade boys, as well as girls, are to be eligible for free human papillomavirus (HPV) vaccines, the Taipei City Government said yesterday. The Taipei Department of Health in ...
- 16 states benefit from HPV vaccination — JSIon May 7, 2024 at 8:32 am
Kogi State, have benefited from the HPV vaccination, whose target population is girls between the ages of 9 and 14 years old, since the campaign started in 2023.The Social Behavioural Change Focal ...
- Taipei expands free HPV vaccine to male junior high studentson May 7, 2024 at 12:21 am
TAIPEI (Taiwan News) — Taipei Mayor Chiang Wan-an (蔣萬安) announced on Tuesday (May 7) that Taipei City will expand the free HPV vaccine program to include male junior high school students.
- HPV vaccine success shown in those who had catch-up immunisationon May 2, 2024 at 9:06 am
HPV vaccination reduced the number of cervical cancer diagnoses by 75% among those who were offered catch up vaccination.
- Cervical cancer vaccine roll-out shows efficacy in reducing cervical cancer and other HPV-related diseaseon April 29, 2024 at 8:51 am
With the creation of safe and efficacious vaccines to target human papillomavirus in the first decade of this century, WHO has an ambitious target to lower cervical cancer incidence (mostly caused by ...
- Namibia struggles with delay in rollout of HPV vaccineon April 26, 2024 at 3:25 pm
Namibia is recognized as one of the few African nations to reach continental health targets outlined in the Abuja Declaration, allocating at least 15% of its national budget to health. Despite that ...
via Google News and Bing News